A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial

Daniel L. Rubin, Terry S. Desser, Richard Semelka, Jeffrey Brown, Hanh V. Nghiem, W. Ross Stevens, David Bluemke, Rendon Nelson, Patrick Fultz, Peter Reimer, Vincent Ho, Rita M. Kristy, Joseph A. Pierro

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences